Furthermore, with the exploration of the BORA silencing transcriptional landscape, we identified downstream effectors such as CDK6 and BCL2 whose inhibition can be used as targeted therapies for ovarian cancer management. The gene discussed is BCL2; the disease is ovarian carcinoma.